Psychoeducation and Well-Being After Breast Cancer (NCT07284030) | Clinical Trial Compass
RecruitingNot Applicable
Psychoeducation and Well-Being After Breast Cancer
Turkey (Türkiye)72 participantsStarted 2025-05-01
Plain-language summary
This randomized controlled trial evaluates the effectiveness of a web-based psychoeducation program on psychological well-being and quality of life in breast cancer survivors who completed active treatment at least one year earlier.
Seventy-two women will be randomly assigned to either a 6-week online psychoeducation program plus standard care or standard care alone. The intervention consists of weekly 30-45 minute online sessions focusing on coping strategies, psychosocial adjustment, quality of life, and psychological well-being.
Primary outcomes include psychological well-being, fear of cancer recurrence, quality of life, and hopelessness, assessed at baseline, post-intervention, and 2-month follow-up.
Who can participate
Age range
18 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female breast cancer survivors
* Completed active breast cancer treatment (surgery, chemotherapy, radiotherapy) at least 12 months ago
* Currently in remission (no evidence of active disease)
* Age between 18-65 years
* Able to read and write Turkish
* Access to computer or smartphone with internet connection
* Able to participate in online video sessions via Zoom
* Willing to provide informed consent
Exclusion Criteria:
* Current cancer recurrence or metastatic disease
* Active psychiatric disorder requiring treatment
* Cognitive impairment that prevents participation in online sessions
* Currently receiving active cancer treatment (excluding hormonal therapy)
* Participation in another psychosocial intervention study
* No internet access or inability to use web-based platforms
* Male breast cancer patients
* Unable to commit to 6-week program schedule
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Psychological Well-Being
Timeframe: Baseline, 6 weeks (post-intervention), and 2-month follow-up
2
Change in Fear of Cancer Recurrence
Timeframe: Baseline, 6 weeks (post-intervention), and 2-month follow-up